HIV Reshaping Treatment Paradigms

Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.

Scope of this report

* In-depth analysis of the current HIV market across the major US and EU markets

* Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

* Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets

* Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors

Research and analysis highlights

By 2016 the HIV market is forecasted to grow to $11.5 billion. This growth will be driven mainly by the increase in numbers of patients accessing treatments as well as the launch of several new drugs and drug classes

The availability of several simple, once-daily treatments such as fixed dose combinations and once daily protease inhibitors has intensified the competition within the respective classes. Adherence to therapy is consequently expected to improve leading to a decline in the number of patients entering late-stage therapy.

The anticipated launches of pipeline antiretrovirals such as CCR5 inhibitors, integrase inhibitors and others, which demonstrate novel activity and efficacy against resistant mutants, will not only offer more variety to patients but will increase the overall value of the market.

Key reasons to read this report

* Understand the constantly evolving market dynamics of antiretroviral drugs

* Understand the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies

* Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2006 to 2016.

Published: 11 July 2007

PDF Format
Table of Contents
Price: $15,200.00 / GBP7,600.00